达格列净对2型糖尿病患者心力衰竭与死亡率的影响
DECLARE-TIMI 58试验事后分析按基线左室射血分数(EF)分层,评估达格列净对2型糖尿病患者心力衰竭与死亡的影响。结果显示达格列净在射血分数降低的心力衰竭(HFrEF)患者中降低心血管死亡/心力衰竭住院复合终点(HR 0.62)、心血管死亡(HR 0.55)和全因死亡(HR 0.59),在无HFrEF患者中仅降低心力衰竭住院(HR 0.76)。
要点
- 达格列净在HFrEF患者中显著降低心血管死亡/心力衰竭住院复合终点(HR 0.62)。
- 达格列净在伴或不伴HFrEF患者中均降低心力衰竭住院(HR 0.64 vs 0.76)。
- 达格列净仅在HFrEF患者中降低心血管死亡和全因死亡(HR 0.55和0.59)。
核心结论
- 达格列净在伴或不伴HFrEF的2型糖尿病患者中均降低心力衰竭住院,仅在HFrEF患者中降低心血管死亡和全因死亡。
主要发现
- 达格列净降低心血管死亡/心力衰竭住院复合终点在HFrEF患者中HR 0.62(95%CI 0.45-0.86),无HFrEF患者中HR 0.88(95%CI 0.76-1.02),交互P=0.046。
- 达格列净降低心力衰竭住院在HFrEF患者中HR 0.64(95%CI 0.43-0.95),无HFrEF患者中HR 0.76(95%CI 0.62-0.92)。
- 达格列净降低心血管死亡仅在HFrEF患者中HR 0.55(95%CI 0.34-0.90),无HFrEF患者中HR 1.08(95%CI 0.89-1.31),交互P=0.012。
- 达格列净降低全因死亡仅在HFrEF患者中HR 0.59(95%CI 0.40-0.88),无HFrEF患者中HR 0.97(95%CI 0.86-1.10),交互P=0.016。
关键数值与推荐
- HFrEF定义为EF<45%。
- 无HFrEF患者中心力衰竭但无已知EF降低者HR 0.88(95%CI 0.66-1.17),无心力衰竭者HR 0.88(95%CI 0.74-1.03)。
临床怎么用
- 对合并HFrEF的2型糖尿病患者,达格列净可降低心血管死亡、全因死亡和心力衰竭住院。
- 对无HFrEF的2型糖尿病患者,达格列净降低心力衰竭住院,但对死亡无明显获益。
局限性
- EF仅在可用时收集,可能存在选择偏倚。
- 为事后分析,HFrEF亚组样本量较小(671例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) on the clinical benefit of sodium-glucose cotransporter 2 inhibition is unknown. METHODS: In the DECLARE-TIMI 58 trial, baseline heart failure (HF) status was collected from all patients, and EF was collected when available. HF with reduced EF (HFrEF) was defined as EF <45%. Outcomes of interest were the composite of cardiovascular death/HHF, its components, and all-cause mortality. RESULTS: Of 17 160 patients, 671 (3.9%) had HFrEF, 1316 (7.7%) had HF without known reduced EF, and 15 173 (88.4%) had no history of HF at baseline. Dapagliflozin reduced cardiovascular death/HHF more in patients with HFrEF (hazard ratio [HR], 0.62 [95% CI, 0.45-0.86]) than in those without HFrEF (HR, 0.88 [95% CI, 0.76-1.02]; P for interaction=0.046), in whom the treatment effect of dapagliflozin was similar in those with HF without known reduced EF (HR, 0.88 [95% CI, 0.66-1.17]) and those without HF (HR, 0.88 [95% CI, 0.74-1.03]). Whereas dapagliflozin reduced HHF both in those with (HR, 0.64 [95% CI, 0.43-0.95]) and in those without HFrEF (HR, 0.76 [95% CI, 0.62-0.92]), it reduced cardiovascular death only in patients with HFrEF (HR, 0.55 [95% CI, 0.34-0.90]) but not in those without HFrEF (HR, 1.08 [95% CI, 0.89-1.31]; P for interaction=0.012). Likewise, dapagliflozin reduced all-cause mortality in patients with HFrEF (HR, 0.59 [95% CI, 0.40-0.88;) but not in those without HFrEF (HR, 0.97 [95% CI, 0.86-1.10]; P for interaction=0.016). CONCLUSIONS: In the first sodium-glucose cotransporter 2 inhibitor cardiovascular outcome trial to evaluate patients with type 2 diabetes mellitus stratified by EF, we found that dapagliflozin reduced HHF in patients with and without HFrEF and reduced cardiovascular death and all-cause mortality in patients with HFrEF. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01730534.
引用
- Kato ET, Silverman MG, Mosenzon O, et al. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019. PMID: 30882238. doi:10.1161/CIRCULATIONAHA.119.040130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。